Comparison of 18F-FDG-PET/CT with 99mTc-MDP bone scintigraphy for the detection of bone metastases in cancer patients

Nuclear Medicine Communications

Volumn 31, Issue 6, 2010, Pages 597-603

  Özülker, Tamer ^a   Küçüköz Uzun, Aysun ^a   Özülker, Filiz ^a   Özpaçac, Tevfik ^a  

^a OKMEYDANI TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

18F fluorodeoxyglucose; Bone metastases; Bone scintigraphy; Oncology; Positron emission tomography computed tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BONE AND BONES; BONE NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77951767695     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328338e909     Document Type: Article

References (26)

1. Padhani A, Husband J. Bone metastases. In: Husband JES, Reznek RH, eds. Imaging in oncology. Oxford, UK: Isis Medical Media Ltd.; 1998. pp. 765-787.
2. Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med 2001; 45:53-64.
3. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol 2004; 22:2942-2953.
4. Tryciecky EW, Gottschalk A, Ludema K. Oncologic imaging: interactions of nuclear medicine with CT and MRI using the bone scan as a model. Semin Nucl Med 1997; 27:142-151.
5. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J. Clin Oncol 1998; 16:3375-3379.
6. Fujimoto R, Higashi T, Nakamoto Y, Hara T, Lyshchik A, Ishizu K, et al. Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET. Ann Nucl Med 2006; 20:399-408.
7. Nakamoto Y, Osman M, Wahl RL. Prevalence and patterns of bone metastases detected with positron emission tomography using 18F-FDG. Clin Nucl Med 2003; 28:302-307.
8. Shie P, Cardarelli R, Brandon D, Erdman W, Abdulrahim N. Meta-analysis: comparison of 18F-fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med 2008; 33:97-101.
9. Uematsu T, Yuen S, Yukisawa S, Aramaki T, Morimoto N, Endo M, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. Am J Roentgenol 2005; 184:1266-1273.
10. Du Y, Cullum I, Illidge TM, Ell PJ. Fusion of metabolic function and morphology: sequential (18F) fluorodeoxyglucose positron-emission tomography/ computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 2007; 25:3440-3447.
11. Huyge V, Garcia C, Vanderstappen A, Alexiou J, Gil T, Flamen P. Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET. Clin Nucl Med 2009; 34:417-420.
12. Liu FY, Chang JT, Wang HM, Liao CT, Kang CJ, Ng SH, et al. [18F]fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol 2006; 24:599-604. Erratum in: J Clin Oncol 2006; 24:3515. Ng, Shu-Kung [corrected to Ng, Shu-Hang].
13. Song JW, Oh YM, Shim TS, Kim WS, Ryu JS, Choi CM. Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer. Lung Cancer 2009; 65:333-338.
14. Min JW, Um SW, Yim JJ, Yoo CG, Han SK, Shim YS, et al. The role of whole-body FDG PET/CT, (Tc-99m) MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer. J Korean Med Sci 2009; 24:275-280.
15. Phan HT, Jager PL, Plukker JT, Wolffenbuttel BH, Dierckx RA. Detection of bone metastases in thyroid cancer patients: bone scintigraphy or 18F-FDG PET? Nucl Med Commun 2007; 28:597-602.
16. Ito S, Kato K, Ikeda M, Iwano S, Makino N, Tadokoro M, et al. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med 2007; 48:889-895.
17. Wu HC, Yen RF, Shen YY, Kao CH, Lin CC, Lee CC. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report. J Cancer Res Clin Oncol 2002; 128:503-506.
18. Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, et al. Comparison between whole-body positron emission tomography and bone scintigraphy in evaluating bony metastases of esophageal carcinomas. Anticancer Res 2005; 25:4439-4444.
19. Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999; 40:1407-1413.
20. Schirrmeister H, Bommer M, Buck AK, Müller S, Messer P, Bunjes D, et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002; 29:361-366.
21. Corcoran RJ, Thrall JH, Kyle RW, Kaminski RJ, Johnson MC. Solitary abnormalities in bone scans of patients with extraosseous malignancies. Radiology 1976; 121:663-667.
22. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[18F]fluoro-D-glucose. Radiology 1996; 199:751-756.
23. Effert PJ, Bares R, Handt S,Wolff JM, Büll U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorinelabeled deoxyglucose. J Urol 1996; 155:994-998.
24. Yeh SD, Imbriaco M, Larson SM, Garza D, Zhang JJ, Kalaigian H. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 1996; 23:693-697.
25. Basu S, Alavi A. Bone marrow and not bone is the primary site for skeletal metastasis: critical role of [18F]fluorodeoxyglucose positron emission tomography in this setting. J Clin Oncol 2007; 25:1297; author reply 1297-1299.
26. Zhuang H, Sam JW, Chacko TK, Duarte PS, Hickeson M, Feng Q, et al. Rapid normalization of osseous FDG uptake following traumatic or surgical fractures. Eur J Nucl Med Mol Imaging 2003; 30:1096-1103.